Antoine Papiernik

Antoine Papiernik, Managing Partner, joined Sofinnova Partners in 1997. Antoine has an MBA from the Wharton School (University of Pennsylvania). He started his career in Private Equity in the Caisse des Dépôts group, first with CDC-Participations, then in its newly formed venture capital arm CDC-Innovation where he invested exclusively in life sciences. Since joining Sofinnova Partners, Antoine has been an initial investor in Actelion (a Swiss biopharmaceuticals company that is now listed on the Zürich stock exchange), as well as NovusPharma (a company listed on the Milan stock exchange that merged with Cell Therapeutics, which is quoted on Nasdaq). He is also an investor in and a board member of Biolipox, Diatos, SpineVision, CoreValve, Addex, Fovea and Lectus.